RESUMO
【Objective】 To investigate the association of maternal medication during early pregnancy and cytochrome P450 (CYP450) genetic polymorphisms with the risk of congenital heart disease (CHD) in offspring. 【Methods】 We selected 127 pregnant women with CHD fetuses as the observation group and 132 pregnant women with non-CHD fetuses as the control group. Their characteristics and medication history were investigated, and CYP450 polymorphisms were detected. Logistic regression analysis was used to assess the association between maternal medication, CYP450 gene variations, and offspring CHD risk. 【Results】 The risk of CHD in offspring was higher in the observation group with maternal use of ovulation induction drugs, antihypertensive drugs, antibiotics, antidepressants, miscarriage prevention drugs, and traditional Chinese medicine (P<0.05). The A/T and T/T genotypes in rs1065852 and the C/G and G/G genotypes in rs16947 increased the risk of CHD in offspring compared to their respective genotypes. The risk of CHDs in offspring increased with the presence of risk genotypes (A/T or T/T) at the rs1065852 locus of the maternal CYP450 gene and early pregnancy medication use (P<0.05); the same was observed for risk genotypes (C/G or G/G) at the rs16947 locus (P<0.05). 【Conclusion】 Maternal medication during early pregnancy may be associated with offspring CHD, and the rs1065852 and rs16947 loci of CYP450 are significantly related to the risk of CHD in offspring.
RESUMO
Objective To investigate the clinical value of serum carbohydrate antigen (CA125,CA199)and vascular endothelial growth factor C (VEGF-C)in early diagnosis of ovarian carcinoma.Methods 51 cases of ovarian cancer patients with retroperitoneal lymph node dissection were performed in the observation group,including 23 cases of ovarian cancer retroperitoneal lymph node metastasis,32 cases of ovarian benign tumor were selected as the control group.The serum levels of CA199 and CA125 were detected by the method of chemiluminescence detection,and the serum VEGF-C level was detected by enzyme-linked immunosorbent assay (ELISA).Results The serum level of CA125 in patients with ovarian cancer (1 682.5 ±261.5)u/mL was significantly higher than that in the control group (30.5 ±6.3)u/mL(P <0.01),serum VEGF-C level in ovarian cancer patients (2 125.6 ±96.7)pg/mL was signif-icantly higher than that in the control group (1 738.0 ±79.8)pg/mL (P <0.01 ).The serum CA199 level of 51 patients with newly diagnosed epithelial ovarian cancer was (72.5 ±30.6)u/mL,serum CA199 level of the control group was (17.4 ±8.5)u/mL,CA199 level of retroperitoneal lymph node metastasis was (134.9 ±72.5)u/mL, ovarian cancer retroperitoneal lymph node metastasis CAl99 serum level were significantly higher than those without lymph node metastasis and the control group (t =7.39,18.34,all P <0.01).The diagnostic sensitivity,specificity and accuracy of serum VEGF-C +CA199 +CA125 in detection of ovarian cancer retroperitoneal lymph node metasta-sis were 95.5%,96.5%,99.5%.Conclusion Combined detection of CA125,VEFG-C and CA199 in serum has important clinical value in predicting lymph node metastasis of ovarian cancer.